Q3 2025 · 13F-HR
ARCH Venture Management, LLCholdings as filed
Filed 2025-11-14 · accession 0001012975-25-000787
$492.4M
Reported value
9
Positions
2025-09-30
Period end
The Brief · ARCH Venture Management, LLC · Q3 2025
AI · grounded in 13F
ARCH Venture Management, LLC established a new position in Rapport Therapeutics Inc. RAPP valued at $110.7M. The fund also initiated new stakes in Beam Therapeutics Inc. BEAM for $110.2M and Maze Therapeutics Inc. MAZE for $106.8M. Other new additions include Vir Biotechnology Inc. VIR at $73.8M and Lyell Immunopharma Inc. LYEL at $44.8M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC. | $110.7M | 22.5% | 3,728,738 | Common | NONE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC. | $110.2M | 22.4% | 4,540,132 | Common | NONE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC. | $106.8M | 21.7% | 4,120,053 | Common | NONE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC. | $73.8M | 15.0% | 12,916,663 | Common | NONE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC. | $44.8M | 9.10% | 2,759,072 | Common | NONE |
| 29479A108 | ERAS | ERASCA INC. | $24.1M | 4.89% | 11,055,554 | Common | NONE |
| 38341P102 | GOSS | GOSSAMER BIO INC. | $21.2M | 4.30% | 8,055,916 | Common | NONE |
| 746964105 | QTTB | Q32 BIO INC. | $634,554 | 0.13% | 320,482 | Common | NONE |
| 71902K402 | CERO | CERO THERAPEUTICS HOLDINGS INC. | $113,960 | 0.02% | 22,389 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.